Role of HDL in neutralizing the VLDL effect on endothelial dysfunction

Microvascular Research

Volumn 89, Issue , 2013, Pages 153-158

  Zago, Valeria ^a   Gorzalczany, Susana ^a   Lucero, Diego ^a   Taira, Carlos ^a   Schreier, Laura ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; NORADRENALIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN LIPID INTERACTION; RAT; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; ATHEROSCLEROSIS; CHOLESTEROL, HDL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEINS; LIPOPROTEINS, VLDL; MALE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; TRIGLYCERIDES; VASODILATION;

EID: 84883139612     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2013.06.002     Document Type: Article

References (30)

1. Adiels M., Borén J., Caslake M.J., Stewart P., Soro A., Westerbacka J., Wennberg B., Olofsson S.O., Packard C., Taskinen M.R. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 2005, 25(8):1697-1703.
2. Adiels M., Olofsson S.O., Taskinen M.R., Borén J. Overproduction of very low density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1225-1236.
3. Barlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 1959, 234:466-468.
4. BIP study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102(1):21-27.
5. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003, 23(2):168-175.
6. Doi H., Kugiyama K., Ohgushi M., Sugiyama S., Matsumura T., Ohta Y., Nakano T., Nakajima K., Yasue H. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis 1998, 137(2):341-349.
7. Ginsberg H.N., Elam M.B., Lovato L.C., Crouse J.R., Leiter L.A., Linz P., Friedewald W.T., Buse J.B., Gerstein H.C., Probstfield J., Grimm R.H., Ismail-Beigi F., Bigger J.T., Goff D.C., Cushman W.C., Simons-Morton D.G., Byington R.P. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. Engl. J. Med. 2010, 362(17):1563-1574.
8. Guide Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals 1996, 21-48. National Academy Press, Washington D.C.
9. Karpe F., Bell M., Björkegren J., Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler. Thromb. Vasc. Biol. 1995, 15(2):199-207.
10. Lewis T.V., Dart A.M., Chin-Dusting J.P. Non-specific inhibition by human lipoproteins of endothelium dependent relaxation in rat aorta may be attributed to lipoprotein phospholipids. Cardiovasc. Res. 1997, 34:590-596.
11. Lewis T.V., Dart A.M., Chin-Dusting J.P. Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol. J. Am. Coll. Cardiol. 1999, 33(3):805-812.
12. Lowry O., Rosebrough N., Farr A., Randall R. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
13. Lucero D., Zago V., López G.H., Cacciagiú L., López G.I., Wikinski R., Nakajima K., Schreier L. Predominance of large VLDL particles in metabolic syndrome, detected by size exclusion liquid chromatography. Clin. Biochem. 2012, 45:293-297.
14. Lundman P., Tornvall P., Nilsson L., Pernow J. A triglyceride-rich fat emulsion and free fatty acids but not very low density lipoproteins impair endothelium-dependent vasorelaxation. Atherosclerosis 2001, 159:35-41.
15. Matsuda Y., Hirata K., Inoue N., Suematsu M., Kawashima S., Akita H., Yokoyama M. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ. Res. 1993, 72:103-109.
16. Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M.H., Ginsberg H.N., Goldberg A.C., Howard W.J., Jacobson M.S., Kris-Etherton P.M., Lennie T.A., Levi M., Mazzone T., Pennathur S. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123(20):2292-2333.
17. Navab M., Hama S.Y., Cooke C.J., Anantharamaiah G.M., Chaddha M., Jin L., Subbanagounder G., Faull K.F., Reddy S.T., Miller N.E., Fogelman A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 2000, 41:1481-1494.
18. Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., Tietge U.J., Gödecke A., Ishii I., Kleuser B., Schäfers M., Fobker M., Zidek W., Assmann G., Chun J., Levkau B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113(4):569-581.
19. Perségol L., Sementa V., Athias A., Lecerf J., Lallemant C., Gambert P. Co-incubation of native and oxidized low-density lipoproteins: potentiation of relaxation impairment. Eur. J. Pharmacol. 2000, 406(3):429-437.
20. Rosenson R.S., Brewer H.B., Davidson W.S., Fayad Z.A., Fuster V., Goldstein J., Hellerstein M., Jiang X.C., Phillips M.C., Rader D.J., Remaley A.T., Rothblat G.H., Tall A.R., Yvan-Charvet L. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012, 25:11905-11919.
21. Rutledge J.C., Mullick A.E., Gardner G., Goldberg I.J. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ. Res. 2000, 86:768-773.
22. Schreier L.E., Sanguinetti S., Mosso H., Lopez G.I., Siri L., Wikinski R.L. Low-density lipoprotein composition and oxidability in atherosclerotic cardiovascular disease. Clin. Biochem. 1996, 29(5):479-487.
23. Schreier L., Berg G., Zago V., Gonzalez A.I., Wikinski R. Kinetics of in vitro lipolysis of human very low-density lipoprotein by lipoprotein lipase. Nutr. Metab. Cardiovasc. Dis. 2002, 12(1):13-18.
24. Schwartz E.A., Reaven P.D. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim. Biophys. Acta 2012, 1821(5):858-866.
25. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J. Lipid Res. 2009, 50:S376-S381.
26. Tso C., Martinic G., Fan W.H., Rogers C., Rye K.A., Barter P.J. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26(5):1144-1149.
27. Wang L., Gill R., Pedersen T.L., Higgins L.J., Newman J.W., Rutledge J.C. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid Res. 2009, 50(2):204-213.
28. Wang W., Hein T.W., Zhang C., Zawieja D.C., Liao J.C., Kuo L. Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase. Microcirculation 2011, 18:36-45.
29. Zago V., Sanguinetti S., Brites F., Berg G., Verona J., Basilio F., Wikinski R., Schreier L. Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women. Atherosclerosis 2004, 177:203-210.
30. Zheng X.Y., Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J. Lipid Res. 2007, 48:1673-1680.